Cyclooxygenase-2 expression in prostate cancer

An inconsistent therapeutic target

Manish Kohli, Richard A. Dennis, Perkins Mukunyadzi, Donald E. Johnson, Varsha Kaushal

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: To determine cyclooxygenase-2 (COX-2) expression patterns in primary prostate tissue of patients undergoing androgen deprivation therapy and in patients with early stage disease. Methods: Gene and protein expression analysis were performed in freshly resected prostate cancer tissue obtained from patients with advanced stage cancer who presented with bladder obstruction (n = 8). Local stage cancer specimens were collected from patients undergoing radical prostatectomy (RP) (n = 10). Expression studies in fresh specimens included quantitative real time polymerase chain reaction, western immunoblotting and immunohistochemistry (IHC). Mean COX-2 gene expressions were compared in both stages. In addition to evaluating protein expression by IHC in fresh specimens, an unrelated archival specimen set of 23 additional clinically matched, advanced and 20 local stage cancer specimens were also analyzed. The pooled (fresh and archival) specimen set (n = 30 each) was then used for evaluating protein expression by IHC. Thirty non-cancer archival specimens with benign prostate hyperplasia were similarly evaluated by IHC. Results: COX-2 m-RNA was detected in all specimens successfully processed for gene expression studies (15/18). No difference was observed in mean gene expression intensities of both stages. Positive expression by immunoblotting was detected in 2/6 advanced and 0/9 local stage specimens. Immunohistochemical analysis of the pooled specimen set detected 4/30 advanced and 0/30 local stage cancer specimen positivity. Positive staining was observed in 2/30 benign hyperplasia specimens as well. Conclusions: COX-2 is expressed inconsistently in prostate tissue of patients undergoing androgen deprivation and is absent in the early stage. Therapeutic targeting with specific inhibitors is therefore likely to benefit a subgroup of patients with advanced stage disease.

Original languageEnglish (US)
Pages (from-to)113-118
Number of pages6
JournalUroOncology
Volume4
Issue number3-4
DOIs
StatePublished - Sep 2004
Externally publishedYes

Fingerprint

Cyclooxygenase 2
Prostatic Neoplasms
Immunohistochemistry
Gene Expression
Prostate
Androgens
Hyperplasia
Neoplasms
Therapeutics
Pseudogenes
Proteins
Prostatectomy
Immunoblotting
Real-Time Polymerase Chain Reaction
Urinary Bladder
Western Blotting
RNA
Staining and Labeling

Keywords

  • Cycloxygenase
  • Hyperplasia
  • Metastasis
  • Prostatic neoplasm

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kohli, M., Dennis, R. A., Mukunyadzi, P., Johnson, D. E., & Kaushal, V. (2004). Cyclooxygenase-2 expression in prostate cancer: An inconsistent therapeutic target. UroOncology, 4(3-4), 113-118. https://doi.org/10.1080/15610950410001732302

Cyclooxygenase-2 expression in prostate cancer : An inconsistent therapeutic target. / Kohli, Manish; Dennis, Richard A.; Mukunyadzi, Perkins; Johnson, Donald E.; Kaushal, Varsha.

In: UroOncology, Vol. 4, No. 3-4, 09.2004, p. 113-118.

Research output: Contribution to journalArticle

Kohli, M, Dennis, RA, Mukunyadzi, P, Johnson, DE & Kaushal, V 2004, 'Cyclooxygenase-2 expression in prostate cancer: An inconsistent therapeutic target', UroOncology, vol. 4, no. 3-4, pp. 113-118. https://doi.org/10.1080/15610950410001732302
Kohli, Manish ; Dennis, Richard A. ; Mukunyadzi, Perkins ; Johnson, Donald E. ; Kaushal, Varsha. / Cyclooxygenase-2 expression in prostate cancer : An inconsistent therapeutic target. In: UroOncology. 2004 ; Vol. 4, No. 3-4. pp. 113-118.
@article{a454fd0f067e4461a98cf09131ffecf9,
title = "Cyclooxygenase-2 expression in prostate cancer: An inconsistent therapeutic target",
abstract = "Objectives: To determine cyclooxygenase-2 (COX-2) expression patterns in primary prostate tissue of patients undergoing androgen deprivation therapy and in patients with early stage disease. Methods: Gene and protein expression analysis were performed in freshly resected prostate cancer tissue obtained from patients with advanced stage cancer who presented with bladder obstruction (n = 8). Local stage cancer specimens were collected from patients undergoing radical prostatectomy (RP) (n = 10). Expression studies in fresh specimens included quantitative real time polymerase chain reaction, western immunoblotting and immunohistochemistry (IHC). Mean COX-2 gene expressions were compared in both stages. In addition to evaluating protein expression by IHC in fresh specimens, an unrelated archival specimen set of 23 additional clinically matched, advanced and 20 local stage cancer specimens were also analyzed. The pooled (fresh and archival) specimen set (n = 30 each) was then used for evaluating protein expression by IHC. Thirty non-cancer archival specimens with benign prostate hyperplasia were similarly evaluated by IHC. Results: COX-2 m-RNA was detected in all specimens successfully processed for gene expression studies (15/18). No difference was observed in mean gene expression intensities of both stages. Positive expression by immunoblotting was detected in 2/6 advanced and 0/9 local stage specimens. Immunohistochemical analysis of the pooled specimen set detected 4/30 advanced and 0/30 local stage cancer specimen positivity. Positive staining was observed in 2/30 benign hyperplasia specimens as well. Conclusions: COX-2 is expressed inconsistently in prostate tissue of patients undergoing androgen deprivation and is absent in the early stage. Therapeutic targeting with specific inhibitors is therefore likely to benefit a subgroup of patients with advanced stage disease.",
keywords = "Cycloxygenase, Hyperplasia, Metastasis, Prostatic neoplasm",
author = "Manish Kohli and Dennis, {Richard A.} and Perkins Mukunyadzi and Johnson, {Donald E.} and Varsha Kaushal",
year = "2004",
month = "9",
doi = "10.1080/15610950410001732302",
language = "English (US)",
volume = "4",
pages = "113--118",
journal = "UroOncology",
issn = "1561-0950",
publisher = "Taylor and Francis Ltd.",
number = "3-4",

}

TY - JOUR

T1 - Cyclooxygenase-2 expression in prostate cancer

T2 - An inconsistent therapeutic target

AU - Kohli, Manish

AU - Dennis, Richard A.

AU - Mukunyadzi, Perkins

AU - Johnson, Donald E.

AU - Kaushal, Varsha

PY - 2004/9

Y1 - 2004/9

N2 - Objectives: To determine cyclooxygenase-2 (COX-2) expression patterns in primary prostate tissue of patients undergoing androgen deprivation therapy and in patients with early stage disease. Methods: Gene and protein expression analysis were performed in freshly resected prostate cancer tissue obtained from patients with advanced stage cancer who presented with bladder obstruction (n = 8). Local stage cancer specimens were collected from patients undergoing radical prostatectomy (RP) (n = 10). Expression studies in fresh specimens included quantitative real time polymerase chain reaction, western immunoblotting and immunohistochemistry (IHC). Mean COX-2 gene expressions were compared in both stages. In addition to evaluating protein expression by IHC in fresh specimens, an unrelated archival specimen set of 23 additional clinically matched, advanced and 20 local stage cancer specimens were also analyzed. The pooled (fresh and archival) specimen set (n = 30 each) was then used for evaluating protein expression by IHC. Thirty non-cancer archival specimens with benign prostate hyperplasia were similarly evaluated by IHC. Results: COX-2 m-RNA was detected in all specimens successfully processed for gene expression studies (15/18). No difference was observed in mean gene expression intensities of both stages. Positive expression by immunoblotting was detected in 2/6 advanced and 0/9 local stage specimens. Immunohistochemical analysis of the pooled specimen set detected 4/30 advanced and 0/30 local stage cancer specimen positivity. Positive staining was observed in 2/30 benign hyperplasia specimens as well. Conclusions: COX-2 is expressed inconsistently in prostate tissue of patients undergoing androgen deprivation and is absent in the early stage. Therapeutic targeting with specific inhibitors is therefore likely to benefit a subgroup of patients with advanced stage disease.

AB - Objectives: To determine cyclooxygenase-2 (COX-2) expression patterns in primary prostate tissue of patients undergoing androgen deprivation therapy and in patients with early stage disease. Methods: Gene and protein expression analysis were performed in freshly resected prostate cancer tissue obtained from patients with advanced stage cancer who presented with bladder obstruction (n = 8). Local stage cancer specimens were collected from patients undergoing radical prostatectomy (RP) (n = 10). Expression studies in fresh specimens included quantitative real time polymerase chain reaction, western immunoblotting and immunohistochemistry (IHC). Mean COX-2 gene expressions were compared in both stages. In addition to evaluating protein expression by IHC in fresh specimens, an unrelated archival specimen set of 23 additional clinically matched, advanced and 20 local stage cancer specimens were also analyzed. The pooled (fresh and archival) specimen set (n = 30 each) was then used for evaluating protein expression by IHC. Thirty non-cancer archival specimens with benign prostate hyperplasia were similarly evaluated by IHC. Results: COX-2 m-RNA was detected in all specimens successfully processed for gene expression studies (15/18). No difference was observed in mean gene expression intensities of both stages. Positive expression by immunoblotting was detected in 2/6 advanced and 0/9 local stage specimens. Immunohistochemical analysis of the pooled specimen set detected 4/30 advanced and 0/30 local stage cancer specimen positivity. Positive staining was observed in 2/30 benign hyperplasia specimens as well. Conclusions: COX-2 is expressed inconsistently in prostate tissue of patients undergoing androgen deprivation and is absent in the early stage. Therapeutic targeting with specific inhibitors is therefore likely to benefit a subgroup of patients with advanced stage disease.

KW - Cycloxygenase

KW - Hyperplasia

KW - Metastasis

KW - Prostatic neoplasm

UR - http://www.scopus.com/inward/record.url?scp=11244255468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11244255468&partnerID=8YFLogxK

U2 - 10.1080/15610950410001732302

DO - 10.1080/15610950410001732302

M3 - Article

VL - 4

SP - 113

EP - 118

JO - UroOncology

JF - UroOncology

SN - 1561-0950

IS - 3-4

ER -